Last reviewed · How we verify
Radioactive Iodine Therapy
Radioactive Iodine Therapy involves the use of radioactive iodine to destroy cancer cells in the thyroid gland.
Radioactive Iodine Therapy involves the use of radioactive iodine to destroy cancer cells in the thyroid gland. Used for Thyroid cancer that has spread to other parts of the body, Thyroid cancer with a high risk of recurrence.
At a glance
| Generic name | Radioactive Iodine Therapy |
|---|---|
| Sponsor | AstraZeneca |
| Target | Thyroid cells |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The radioactive iodine is selectively taken up by the thyroid cells, where it emits radiation that kills the cancer cells. This treatment is often used for patients with thyroid cancer that has spread to other parts of the body or for patients who have a high risk of recurrence.
Approved indications
- Thyroid cancer that has spread to other parts of the body
- Thyroid cancer with a high risk of recurrence
Common side effects
- Thyroid dysfunction
- Salivary gland dysfunction
- Xerostomia
- Nausea and vomiting
- Fatigue
Key clinical trials
- Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (PHASE2)
- Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma (PHASE2)
- Empirical Radioactive Iodine Therapy in DTC (PHASE1, PHASE2)
- Iodine Uptake After a Low Iodine Diet (NA)
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
- Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation (PHASE2)
- CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer
- Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |